Showing 4691-4700 of 6945 results for "".
- Two New Options for After-Sun Care Launchedhttps://practicaldermatology.com/news/two-new-options-after-sun-care-launched/2467968/San Diego-based skincare company Terns announced today that it has launched two new after-sun care products targeting outdoor enthusiasts. The products, which include a range of creams and gels, are formulated with the proprietary Sirenas Complex, which the manufacturer said is derived f
- Study Aims to Define Photosensitivity Diagnosis in Atopic Dermatitishttps://practicaldermatology.com/news/study-aims-define-photosensitivity-diagnosis-atopic-dermatitis/2467967/A new study aims to refine diagnostic criteria for photosensitivity in patients with atopic dermatitis (AD). “Previous reports have characterized photosensitivity in AD, but with differences in terminology and criteria,” the authors noted, suggesting a need for better guidance. The
- European Commission Approves Celltrion’s Stelara Biosimilar SteQeymahttps://practicaldermatology.com/news/european-commission-approves-celltrions-stelara-biosimilar-steqeyma/2467952/Celltrion announced that the European Commission (EC) has approved SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases, including psoriasis. The EC's approval follows a positive opinion from the Committee for Medici
- Study: LTX-315 Shows 86% Reduction in BCC Tumor Sizehttps://practicaldermatology.com/news/study-ltx-315-shows-86-reduction-bcc-tumor-size/2467796/Lytix Biopharma has announced promising preliminary results from a phase 2 clinical trial evaluating the efficacy of LTX-315, its candidate drug for the treatment of basal cell carcinoma (BCC). The trial was conducted by Verrica Pharmaceuticals, according to a news release, and the result
- New Plasma Proteins Linked to Atopic Dermatitis Riskhttps://practicaldermatology.com/news/new-plasma-proteins-linked-atopic-dermatitis-risk/2467771/New research has identified eight plasma proteins associated with atopic dermatitis (AD), potentially opening new avenues for treatment. Publishing in the Archives of Dermatological Research, the study authors used summary-data-based Mendelian Randomization (SMR) and evaluated dat
- FDA Approves Nemluvio for Prurigo Nodularis Treatmenthttps://practicaldermatology.com/news/fda-approves-nemluvio-prurigo-nodularis-treatment/2467770/The U.S. Food and Drug Administration (FDA) has approved Galderma's Nemluvio® (nemolizumab) for the treatment of adults with prurigo nodularis, according to a news release. Nemolizumab, a monoclonal antibody IL-31 inhibitor, targets a neuroimmune cytokine implicated in prurigo nodularis p
- Dietary Sodium Intake Linked to Increased Atopic Dermatitis Riskhttps://practicaldermatology.com/news/dietary-sodium-intake-linked-increased-atopic-dermatitis-risk/2467760/Higher dietary sodium intake has been associated with an increased risk and severity of atopic dermatitis (AD), according to new research in JAMA Dermatology. Researchers for the cross-sectional analysis examined 215,832 participants aged 37-73 years from a UK Biobank cohort using 24-hour
- Five-Year Study Validates Dupilumab for Atopic Dermatitis Managementhttps://practicaldermatology.com/news/five-year-study-validates-dupilumab-atopic-dermatitis-management/2467714/New research has provided evidence of benefit from a long-term strategy of dupilumab for the treatment of atopic dermatitis (AD). Researchers for the multicenter cohort study looked at clinical effectiveness, response times, and reasons for discontinuation of dupilumab treatment over a pe
- Galderma to Pursue a Scientific Partnership with L’Oréalhttps://practicaldermatology.com/news/galderma-to-pursue-a-scientific-partnership-with-loreal/2467670/Galderma has signed a memorandum of understanding with L’Oréal to work toward a new research and development (R&D) collaboration in the form of a scientific partnership, according to a company news release. The partnership would
- European Committee Recommends Approval of Delgocitinib for CHEhttps://practicaldermatology.com/news/european-committee-recommends-approval-delgocitinib-che/2467631/The European Medicine Agency Committee for Medicinal Products for Human Use (CHMP) has “adopted a positive opinion that recommends the approval” of delgocitinib cream for the treatment of adult patients with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequ